Creative Medical Technology Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.4%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 22 Mar 2027 |
Monitoring Framework
Key Performance Indicators
CELZ-201 (Olastrocel) ADAPT Trial Patient Follow-up Completion Quarterly180.0Target: 360-day safety and efficacy follow-up
Ultrasome™ Knee Osteoarthritis Program Response Rate Annually9,300.0%Target: Maintain high efficacy in expanded clinical cohorts
Cash and Cash Equivalents Quarterly5.7MTarget: Sufficient capital to fund operations without immediate dilutive fundraising
Watch Items
- FDA Late-Stage Regulatory Engagement for CELZ-201-DDTTrigger: Topline data readout from the ADAPT trialAction: Initiate formal discussions for Phase III trial design or accelerated approval pathways under Fast Track status.
- Project PHOENIX AI-Driven Registry EnrollmentTrigger: Enrollment of at least 1,000 U.S. veteransAction: Analyze multi-omics data to identify therapeutic targets for toxic-exposure-related injuries.
- Capital Runway and Dilution RiskTrigger: Cash balance falling below $3.0 millionAction: Evaluate strategic partnerships, non-dilutive biodefense grants, or structured warrant exercises to extend runway.
Research as of 20 Jun 2026